COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
23 hedge funds and large institutions have $631K invested in COSCIENS Biopharma Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 7 closing their positions.
0% less ownership
Funds ownership: 0.02% → 0.01% (-0%)
5% less capital invested
Capital invested by funds: $668K → $631K (-$36.3K)
21% less funds holding
Funds holding: 29 → 23 (-6)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
65% less call options, than puts
Call options by funds: $110K | Put options by funds: $315K
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$12.3K |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$10.8K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.05K |
| 4 |
VF
Virtu Financial
New York
|
+$1.91K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$971 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$68.8K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$61K |
| 3 |
Renaissance Technologies
New York
|
-$51.6K |
| 4 |
Millennium Management
New York
|
-$20K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$16.1K |
CSCI Hedge Fund Activity: Q1 2022 in Review
23 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q1 2022, worth a combined $631K — down 5.4% from $668K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CSCI and 2 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 5 added.
The largest buyer was Morgan Stanley, adding an estimated $12.3K. The largest seller was Citadel Advisors, exiting entirely with an estimated $68.8K sold.
- 23 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q1 2022, down from 29 in Q4 2021.
- Funds reported $631K of COSCIENS Biopharma Inc. Common Stock stock for Q1 2022, down 5.4% quarter-over-quarter.
- 2 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q1 2022 and 7 closed out, a net change of -5 holders.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q1 2022 was Morgan Stanley, an estimated $12.3K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q1 2022 was Citadel Advisors, an estimated $68.8K sold.
Based on aggregated 13F filings for Q1 2022.